Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Jabak and Najjari Discussed the Cooperation between Lebanon and Egypt in the Exchange of Medicines

 
Minister of Public Health Jamil Jabak received UN Special coordinator for Lebanon Philippe Lazzarini. Both discussed the collaboration between the Ministry of Public Health and all the UN organizations working in Lebanon, such as UNIFIL, UNRWA or UNESCO. Lazzarini reiterated the continuing support to the activities of the Ministry of Public Health and follow-up of the donor countries’ programs that are related to the health care sector, in addition to building a joint collaboration in development projects between Lebanon and the United Nations and working on the establishment of better relationships.
 
The Egypt ambassador Nazih Najjari visited also Minister Jabak and stressed the importance of the economic collaboration between the two countries, in particular in the field of medicines. Najjari hoped that Jabak would review the hospitalization systems related to the Egyptian community in Lebanon and whether it is possible to develop the systems while paying attention to the health conditions of the community.
 
Jabak also met with UNRWA Director General in Lebanon Claudio Cordone who presided over a delegation from the agency. “The meeting discussed the collaboration between both parties to ensure the access of Palestinians in Lebanon to health, medical and hospitalization services they need,” Cordone stated.
 
Jabak received a delegation from the board of pharmacists in Lebanon headed by Ghassan Al Amin. Both discussed the situation of health care sector in Lebanon, in particular the medicines dossier and the ways to reduce their costs. It was agreed to form a joint committee to discuss the means to achieve this goal.
 
Jabak then met with the ambassador of the Association of the Malta knights Henry D’Aragon accompanied by the chargé d’affaires François Abi Saab and the representative of the association at the Ministry Khaled Kaskas. D’Aragon stressed the Association’s commitment to preserve the best relationships with Lebanon, indicating readiness to develop and improve them.
    ...
    58
    ...
ATC Name B/G Ingredients Dosage Form Price
A10AB01 JUSLINE R BioTech Insulin (human) - 100IU/ml 100IU/ml Injectable solution 401,809 L.L
L04AA33 ENTYVIO BioTech Vedolizumab - 108mg 108mg Injectable solution 88,955,869 L.L
L01FF01 OPDIVO BioTech Nivolumab - 100mg/10ml 100mg/10ml Injectable solution L.L
A10AB04 HUMALOG KWIKPEN BioTech Insulin lispro - 100IU/ml 100IU/ml Injectable solution 3,950,897 L.L
L04AA33 ENTYVIO BioTech Vedolizumab - 108mg 108mg Injectable solution 88,955,869 L.L
L01FF01 OPDIVO BioTech Nivolumab - 40mg/4ml 40mg/4ml Injectable solution L.L
A10AB04 PROLOG BioTech Insulin lispro - 100U/ml 100U/ml Injectable solution 637,365 L.L
L04AA36 OCREVUS BioTech Ocrelizumab - 300mg/10ml 300mg/10ml Injectable concentrate for solution 547,517,314 L.L
L01FG02 CYRAMZA BioTech Ramucirumab - 500mg/50ml 500mg/50ml Injectable solution L.L
A10AB04 PROLOG BioTech Insulin lispro - 100U/ml 100U/ml Injectable solution 2,126,343 L.L
A10AB04 PROLOG BioTech Insulin lispro - 100U/ml 100U/ml Injectable solution 883,480 L.L
A10AB04 HUMALOG BioTech Insulin lispro - 100IU/ml 100IU/ml Injectable suspension 1,988,887 L.L
L04AC05 STELARA BioTech Ustekinumab - 90mg 90mg Injectable solution L.L
A10AB04 PROLOG BioTech Insulin lispro - 100U/ml 100U/ml Injectable suspension 1,503,312 L.L
L01FA01 MABIXEN 100 BioTech Rituximab - 100mg/10ml 100mg/10ml Injectable concentrate for solution 22,183,393 L.L
B02BD02 XYNTHA BioTech Moroctocog alfa - 500IU 500IU Injectable lyophilised powder for solution+diluent L.L
A10AB05 NOVORAPID FLEXPEN BioTech Insulin aspart - 100IU/ml 100IU/ml Injectable solution 3,123,090 L.L
L01FA01 MABIXEN 100 BioTech Rituximab - 100mg/10ml 100mg/10ml Injectable concentrate for solution 11,091,696 L.L
A10AB05 NOVORAPID FLEXPEN BioTech Insulin aspart - 100IU/ml 100IU/ml Injectable solution 3,123,090 L.L
L01FA01 MABTHERA BioTech Rituximab - 100mg/10ml 100mg/10ml Injectable concentrated solution 35,722,424 L.L
L01FC01 DARZALEX BioTech Daratumumab - 400mg/20ml 400mg/20ml Injectable concentrate for solution L.L
A10AB05 NOVORAPID FLEXPEN BioTech Insulin aspart - 100IU/ml 100IU/ml Injectable solution 3,123,090 L.L
L01FA01 RITUXIREL BioTech Rituximab - 100mg 100mg/10ml Injectable concentrated solution 11,708,063 L.L
L04AA52 KESIMPTA BioTech Ofatumumab - 20mg/0.4ml 20mg/0.4ml Injectable solution 96,542,598 L.L
A10AB06 APIDRA SOLOSTAR BioTech Insulin glulisine - 100IU/ml 100IU/ml Injectable solution 3,942,834 L.L
L01FA01 RIXATHON BioTech Rituximab - 100mg/10ml 100mg/10ml Injectable concentrate for solution 27,354,833 L.L
L04AB01 ALTEBREL BioTech Etanercept - 50mg/1ml 50mg/1ml Injectable solution 14,833,767 L.L
A10AB06 APIDRA BioTech Insulin glulisine - 100IU/ml 100IU/ml Injectable solution 2,221,372 L.L
L01FA01 RUXIENCE BioTech Rituximab - 100mg/10ml 100mg/10ml Injectable concentrate for solution 13,157,756 L.L
L04AB01 ENBREL BioTech Etanercept - 50mg 50mg Injectable solution 52,197,598 L.L
    ...
    58
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025